Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only._x000D_
_x000D_
#What Are the Latest Market Insights for the Cancer Gene Therapy Industry?#_x000D_
In recent times, the market size of cancer gene therapy has seen a quick expansion. The market is projected to rise from $3.61 billion in 2024 to $4.21 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 16.6%. The historic period growth is attributed to increasing awareness about cancers related to oncovirus, partnerships between academic institutions and biotech companies, a rise in clinical trials for early-stage gene therapies, a growing demand for ex vivo modified cell therapies, as well as an influx in strategic licensing agreements for gene therapy platforms._x000D_
_x000D_
The market size of cancer gene therapy is anticipated to witness a speedy expansion in the forthcoming years. With a compound annual growth rate (CAGR) of 16.2%, it is predicted to rise to $7.67 billion by the year 2029. This increase during the projected period could be ascribed to a heightened concentration on non-viral delivery methods, augmented access to companion diagnostics, mounting fascination in off-the-shelf allogeneic cell treatments, upward expansion of contract development and manufacturing organizations (CDMOs) and progressing synthetic biology promoting customizable gene circuits. Noteworthy tendencies during the projection period consist of progression in non-viral gene delivery platforms, sophisticated automation in gene therapy manufacturing, creation of synthetic promoters for specific cancer expression, innovations in intratumoral gene therapy administration, and the evolution of multiplexed gene modulation tactics._x000D_
_x000D_
#Download The Free Sample Report Here:#_x000D_
https://www.thebusinessresearchcompany.com/sample.aspx?id=27233&type=smp_x000D_
_x000D_
#What Forces Are Driving The Growth Of The Cancer Gene Therapy Industry?#_x000D_
The growth of the cancer gene therapy market is predicted to be fueled by the escalating occurrence of cancer. Cancer, a malady typified by the unchecked proliferation of irregular cells that can infiltrate and metastasize to other body parts, springs from various tissues and organs and is categorized based on the originating cell or tissue type. The propensity for cancer onset increases with age and hence with life expectancy on the rise, so are cancer cases. In treating cancer, cancer gene therapy plays a crucial role by modifying or supplanting erroneous genes to inhibit cancer cell propagation or amplify the immune system’s capabilities to eradicate them. For example, Macmillan Cancer Support, a UK-based group, reported in August 2024 that over 3 million people in the UK have cancer. It’s forecasted that these numbers will rise to 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. Hence, the escalating occurrence of cancer is spurring the cancer gene therapy market’s growth._x000D_
_x000D_
#What Is The Overview Of Market Segmentation In The Cancer Gene Therapy Industry?#_x000D_
The cancer gene therapy market covered in this report is segmented_x000D_
_x000D_
1) By Therapy: Gene Induced Immunotherapy, Oncolytic Virotherapy, Gene Transfer_x000D_
2) By Indication: Large B-Cell Lymphoma, Multiple Myeloma, Acute Lymphoblastic Leukemia (ALL), Melanoma (lesions), Other Indications_x000D_
3) By Vector Type: Lentivirus, RetroVirus And Gamma RetroVirus, Adeno-Associated Virus (AAV), Modified Herpes Simplex Virus, Adenovirus, Other Vector Types_x000D_
4) By End-User: Hospitals, Research Institutes, Biopharma Companies, Diagnostic centers, Other End Users_x000D_
_x000D_
Subsegments:_x000D_
1) By Gene Induced Immunotherapy: CAR-T Cell Therapy, TCR (T-Cell Receptor) Therapy, Tumor-Infiltrating Lymphocyte (TIL) Therapy, Dendritic Cell-Based Gene Therapy, NK Cell Gene Therapy_x000D_
2) By Oncolytic Virotherapy: Adenoviruses, Herpes Simplex Virus (HSV), Reovirus, Vaccinia Virus, Newcastle Disease Virus (NDV)_x000D_
3) By Gene Transfer: Viral Gene Transfer, Non-Viral Gene Transfer_x000D_
_x000D_
#What Future Market Trends Are Projected For The Cancer Gene Therapy Industry?#_x000D_
Leading firms within the cancer gene therapy market are investing their efforts into creating specialized treatments, like CAR-T cell therapy, to increase precision in cancer treatments, offer improved outcomes for patients, and effectively target cancer cells whilst reducing harm to non cancerous tissue. The CAR-T therapy is a sophisticated technique in which a patient’s immune cells are modified to increase their efficiency in locating and obliterating cancer cells through the addition of specialized receptors. For example, in April 2024, ImmunoACT, a biotech corporation based in India, introduced NexCAR19 (actalycabtagene autoleucel), the first CAR-T cell therapy in the country developed indigenously for cancer treatment. Its specific design focuses on treating B-cell lymphomas and leukemias, with NexCAR19 functioning through reprogramming a patient’s distinct T cells to recognize and eradicate cancer cells. Utilizing the cutting-edge chimeric antigen receptor (CAR) technology, this locally-produced therapy provides a more cost-effective and easily obtainable alternative to imported versions. This significant product launch demonstrates India’s entrance into the global cancer gene therapy market and emphasizes substantial advancements in native innovation and individually tailored cancer treatments._x000D_
_x000D_
#Who Are The Primary Players Operating Across The Global Cancer Gene Therapy Market?#_x000D_
Major companies operating in the cancer gene therapy market are Bristol Myers Company, Novartis AG, GSK plc., Gilead Sciences Inc., Amgen Inc., Orchard Therapeutics Plc, Biogen Inc., Sarepta Therapeutics Inc., AGC Biologics, Adaptimmune Limited, Sibiono, Elevate Bio Inc., Bluebird Bio Inc., Uniqure N.V., Shanghai Sunway Biotech Co. Ltd., Anges Inc., Gensight Biologics, Genelux Corporation, Cellectis, and Abeona Therapeutics Inc. _x000D_
_x000D_
#Get The Full Report Here:#_x000D_
https://www.thebusinessresearchcompany.com/report/cancer-gene-therapy-global-market-report_x000D_
_x000D_
#Which Region Offers The Most Growth Potential For The Cancer Gene Therapy Market Through 2029?#_x000D_
North America was the largest region in the cancer gene therapy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer gene therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_
_x000D_
#Request For A Customized Report:#_x000D_
https://www.thebusinessresearchcompany.com/customise?id=27233&type=smp_x000D_
_x000D_
#About The Business Research Company:#_x000D_
_x000D_
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_
_x000D_
#Get in touch with us:#_x000D_
_x000D_
The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_
Americas +1 310-496-7795_x000D_
Asia +44 7882 955267 & +91 8897263534_x000D_
Europe +44 7882 955267_x000D_
Email us at info@tbrc.info_x000D_
_x000D_
#Follow us on:#_x000D_
_x000D_
LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model